Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Takeda Seeks A Crescendo With Collaboration On New Type Of Cancer Compound

Executive Summary

AstraZeneca concludes week of four out-licensing transactions by selling US rights to Toprol XL to Aralez and ex-US rights to Rhinocort Aqua to J&J. Molecular Partners gets back rights to an IL-13/IL-17 inhibitor for pulmonary indications after a 2011 deal with Janssen unravels.

Advertisement

Related Content

Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
AstraZeneca Looks To Insmed To Advance AZD7986 In Bronchiectasis
Intas Builds Europe Scale With £603m Teva Deal
Sarepta’s $852m Summit Collaboration Could Enable DMD Drug Combinations
Allergan Licenses MEDI2070, As AstraZeneca Continues Non-Core Exits
PharmaMar Aims For A Second Marketed Product With EU Aplidin Filing
Crescendo Biologics Evolves in Immuno-Oncology Under New Management
Stendra Gets Its 15 Minutes, With New FDA-Approved ED Claim
Merck signs fresh agreement with biotech Nuevolution

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC097442

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel